Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Application of mechanical-force sensitive macrophage subset in pancreatic cancer diagnosis or prognosis evaluation
US12365901B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12365901-B2 |
| Application number | US-202418793716-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 2, 2024 |
| Priority date | Nov 23, 2023 |
| Publication date | Jul 22, 2025 |
| Grant date | Jul 22, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is an application of a mechanical force sensitive macrophage subset in pancreatic cancer diagnosis or prognosis evaluation, in which it is found that a number of mechanical force sensitive macrophages of CD68 + p-PYK2 + YAP1 + in pancreatic cancer is obviously higher than that of an adjacent normal tissue, and the number of the macrophages is in positive correlation with a pancreatic cancer process, so that the mechanical force sensitive macrophages can be used as a pancreatic cancer diagnosis and prognosis index. An elasticity modulus of the cells is reduced by inhibiting a mechanical force check point PYK2 of monocytes/macrophages, and differentiation of the monocytes into the macrophages is inhibited, so that a tumor micro-environment of the pancreatic cancer is improved. Growth of the pancreatic cancer is remarkably inhibited through combined treatment, and the lifetime of mice with the pancreatic cancer is remarkably prolonged.
First claim
Opening claim text (preview).
I claim: 1. A pharmaceutical composition comprising a Proline-Rich Tyrosine Kinase 2 (PYK2) inhibitor in combination with a Programmed Cell Death Protein 1 (PD-1) immunosuppressant for treating pancreatic cancer, which PYK2 inhibitor comprises a siRNA or sgRNA/CRISPR specifically targeting Ptk2b and consisting of SEQ ID NO. 1-6, and/or a Cre-loxP gene knock-out reagent with Ptk2b as a target gene PD-1, which immunosuppressant optionally comprises a PD-1 antibody. 2. The application according to claim 1 , the PYK2 inhibitor is capable of reducing an elastic modulus of cells or inhibiting differentiation of monocytes into macrophages. 3. The application according to claim 1 , wherein the PD-1 immunosuppressant is an αPD-1 antibody.
Assignees
Inventors
Classifications
against CD28 or CD152 · CPC title
against tumor tissues, cells, antigens · CPC title
interfering nucleic acids [NA] · CPC title
- A61P35/00Primary
Antineoplastic agents · CPC title
Combination therapy · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12365901B2 cover?
- Disclosed is an application of a mechanical force sensitive macrophage subset in pancreatic cancer diagnosis or prognosis evaluation, in which it is found that a number of mechanical force sensitive macrophages of CD68 + p-PYK2 + YAP1 + in pancreatic cancer is obviously higher than that of an adjacent normal tissue, and the number of the macrophages is in positive correlation with a pancreatic…
- Who is the assignee on this patent?
- Jiang Hong
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).